Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE
Conclusions: Clopidogrel–aspirin treatment may have a benefit of reducing stroke risk outweighing the potential risk of increased bleeding especially within the first 2 weeks compared with aspirin alone in patients with minor stroke or TIA. Clinicaltrials.gov identifier: NCT00979589. Classification of evidence: This study provides Class II evidence that for patients with minor stroke or TIA, the reduction of stroke risk from clopidogrel plus aspirin within the first 2 weeks outweighs the risk of bleeding compared with aspirin alone.
Source: Neurology - May 15, 2017 Category: Neurology Authors: Pan, Y., Jing, J., Chen, W., Meng, X., Li, H., Zhao, X., Liu, L., Wang, D., Johnston, S. C., Wang, Y., Wang, Y., On behalf of the CHANCE investigators Tags: All Cerebrovascular disease/Stroke, Clinical trials Randomized controlled (CONSORT agreement) ARTICLE Source Type: research

Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke
Conclusions: GA could be a potential biomarker to predict the effects of dual and single antiplatelet therapy in patients with minor stroke or TIA.
Source: Neurology - March 30, 2015 Category: Neurology Authors: Li, J., Wang, Y., Wang, D., Lin, J., Wang, A., Zhao, X., Liu, L., Wang, C., Wang, Y., On behalf of the CHANCE Investigators Tags: Other cerebrovascular disease/ Stroke, Prognosis, All Cerebrovascular disease/Stroke, Infarction ARTICLE Source Type: research

Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis Stroke
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke.
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research

Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up
In conclusion, clopidogrel is suggested for patients with an ESRS >  3 and aspirin for patients with an ESRS ≤ 3 for the secondary prevention of noncardioembolic ischemic stroke in Chinese patients.
Source: Translational Stroke Research - December 30, 2016 Category: Neurology Source Type: research

CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy
This study measures effect ofCYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability ofCYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time<1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or ...
Source: Translational Stroke Research - February 21, 2021 Category: Neurology Source Type: research

Effect of addition of clopidogrel to aspirin on stroke incidence: Meta‐analysis of randomized trials
ConclusionsThis meta‐analysis demonstrates a substantial relative risk reduction in stroke by clopidogrel plus aspirin vs. aspirin alone that is consistent across different trial cohorts. Major haemorrhage is increased by dual antiplatelet therapy.
Source: International Journal of Stroke - May 22, 2013 Category: Neurology Authors: Santiago Palacio, Robert G. Hart, Lesly A. Pearce, David C. Anderson, Mukul Sharma, Lee A. Birnbaum, Oscar R. Benavente Tags: Research Source Type: research

Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
DiscussionAspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Source: International Journal of Stroke - July 23, 2013 Category: Neurology Authors: S. Claiborne Johnston, J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon N. Poisson, Yuko Palesch Tags: Protocols Source Type: research

Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic Attack Brief Reports
Conclusions— Elevated sCD40L levels independently predict recurrent stroke in patients with minor stroke and transient ischemic attack. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Li, J., Wang, Y., Lin, J., Wang, D., Wang, A., Zhao, X., Liu, L., Wang, C., Wang, Y., on behalf of the CHANCE Investigators Tags: Secondary prevention, Risk Factors, Acute Cerebral Infarction Brief Reports Source Type: research

Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA
Conclusions: The presence of multiple infarctions and ICAS were both associated with an increased risk of 90-day ischemic stroke in patients with minor stroke or TIA, while the presence of both imaging features had a combined effect. ClinicalTrials.gov identifier: NCT00979589.
Source: Neurology - March 12, 2017 Category: Neurology Authors: Pan, Y., Meng, X., Jing, J., Li, H., Zhao, X., Liu, L., Wang, D., Johnston, S. C., Wang, Y., Wang, Y., On behalf of the CHANCE Investigators Tags: All Cerebrovascular disease/Stroke, Clinical trials Observational study (Cohort, Case control) ARTICLE Source Type: research

Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin Brief Report
Conclusions—Among patients who experience an ischemic stroke or transient ischemic attack while on aspirin monotherapy, the addition of or a switch to another antiplatelet agent, especially in the first days after index event, is associated with fewer future vascular events, including stroke.
Source: Stroke - August 28, 2017 Category: Neurology Authors: Meng Lee, Jeffrey L. Saver, Keun-Sik Hong, Neal M. Rao, Yi-Ling Wu, Bruce Ovbiagele Tags: Secondary Prevention, Meta Analysis, Ischemic Stroke, Transient Ischemic Attack (TIA) Brief Reports Source Type: research

Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study
ConclusionsEarly dual therapy with clopidogrel and aspirin reduces microembolic signals in patients with minor ischemic stroke or transient ischemic attack, without causing significant bleeding complications.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Alexander Y. Lau, Yudong Zhao, Christopher Chen, Thomas W. Leung, Jianhui Fu, Yining Huang, Nijasri C. Suwanwela, Zhao Han, Kay Sin Tan, Disya Ratanakorn, Hugh S. Markus, Ka Sing Wong, Tags: Clinical Trial Source Type: research

Differences in ischemic and hemorrhagic recurrence rates among race‐ethnic groups in the PRoFESS secondary stroke prevention trial
ConclusionsWe found a significant difference in myocardial infarction and symptomatic intracerebral hemorrhage recurrence among different race‐ethnic groups. The risk of recurrent ischemic and hemorrhagic stroke was greater in Asians with high blood pressure.
Source: International Journal of Stroke - March 18, 2014 Category: Neurology Authors: Conrado J. Estol, Philip M. W. Bath, Philip B. Gorelick, Daniel Cotton, Renee Hebert Martin, Tags: Research Source Type: research

Cost-Effectiveness of Clopidogrel-Aspirin Versus Aspirin Alone for Acute Transient Ischemic Attack and Minor Stroke Stroke
Conclusions Early 90-day clopidogrel-aspirin regimen for acute TIA or minor stroke is highly cost-effective in China. Although clopidogrel is generic, Plavix is brand in China. If Plavix were generic, treatment with clopidogrel-aspirin would have been cost saving.
Source: JAHA:Journal of the American Heart Association - June 5, 2014 Category: Cardiology Authors: Pan, Y., Wang, A., Liu, G., Zhao, X., Meng, X., Zhao, K., Liu, L., Wang, C., Johnston, S. C., Wang, Y., Wang, Y., the CHANCE Investigators Tags: Stroke Source Type: research

Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy
Conclusions: In patients with minor stroke or TIA, the combination of clopidogrel and aspirin appears to be superior to aspirin alone in improving the 90-day functional outcome, and this is consistent with a reduction in the rate of disabling stroke in the dual antiplatelet arm. Classification of evidence: This study provides Class II evidence that for patients with acute minor stroke or TIA, clopidogrel plus aspirin compared to aspirin alone improves 90-day functional outcome (absolute reduction of poor outcome 1.70%, 95% confidence interval 0.03%–3.42%).
Source: Neurology - August 17, 2015 Category: Neurology Authors: Wang, X., Zhao, X., Johnston, S. C., Xian, Y., Hu, B., Wang, C., Wang, D., Liu, L., Li, H., Fang, J., Meng, X., Wang, A., Wang, Y., Wang, Y., For the CHANCE investigators Tags: Stroke prevention, Clinical trials Randomized controlled (CONSORT agreement), Class II, Infarction ARTICLE Source Type: research

Short-term Bleeding Events Observed with Clopidogrel Loading in Acute Ischemic Stroke Patients
Discussion: Contrary to our original hypothesis, patients with AIS receiving clopidogrel loading doses within 24 hours of symptom onset did not appear to experience a higher rate of new serious bleeding events during acute hospitalization when compared with patients who did not receive loading doses. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke trial is expected to provide insight into the safety of clopidogrel loading as an acute intervention after cerebral ischemia.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Lester Y. Leung, Karen C. Albright, Amelia K. Boehme, Joseph Tarsia, Kamal R. Shah, James E. Siegler, Erica M. Jones, Gayle R. Pletsch, Timothy M. Beasley, Sheryl Martin-Schild Tags: Original Articles Source Type: research